Pay in 4 interest-free payments of $37.19 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
more potently in PTEN-positive DU145 cells than in PTEN-negative PC-3 cells
N Engl J Med
InChiKey: HLRQYOGLZWIOPA-UHFFFAOYSA-N
30(3):269-271
25-12 of around 14 000 h•ng/mL contributed to an excellent oral bioavailability of PQR-309 (>50%)
Pomalidomide HCl more potently in PTEN-positive DU145Pomalidomide, also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8,
US$ 24.99
US$ 49.99
US$ 34.99